Biohaven .(US:BHVN) Prnewswireยท2025-09-09 13:00Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that affected investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, for treating SCA, and the sufficiency of data submitted for its regulatory approval [2]. - It is also alleged that the efficacy and clinical prospects of BHV-7000 as a treatment for bipolar disorder were overstated [2]. - The lawsuit suggests that the revelation of these issues would likely have a significant negative impact on Biohaven's business and financial condition, rendering the defendants' public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].